Neoadjuvant Chemotherapy Increases Risk of Postoperative DVT in Distal Pancreatectomy for Pancreatic Adenocarcinoma

Patients with pancreatic adenocarcinoma who undergo distal pancreatectomy and receive neoadjuvant chemotherapy (NAT) are 73% more likely to develop postoperative deep venous thrombosis (DVT) compared to those who undergo upfront resection. This association is significant and highlights the need to prioritize high-risk patients for extended duration prophylaxis. The study analyzed data from 4327 patients using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database, emphasizing the importance of considering NAT when assessing postoperative morbidity and implementing preventive measures.